Comparative Pharmacology
Head-to-head clinical analysis: HALDOL SOLUTAB versus PROLIXIN ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL SOLUTAB versus PROLIXIN ENANTHATE.
HALDOL SOLUTAB vs PROLIXIN ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Category C
Category C
Antipsychotic
Antipsychotic